1. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, Saemundsdottir J, Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Georgsson G, Gretarsdottir OS, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO, Jonasdottir A, Jonsson F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L, Sigmundsdottir G, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Löve A, Masson G, Jonsdottir I, Möller AD, Gudnason T, Kristinsson KG, Thorsteinsdottir U, Stefansson K (2020) Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. doi:10.1056/NEJMoa2006100
2. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323 (13):1239-1242. doi:10.1001/jama.2020.2648
3. Gentile S, Strollo F, Ceriello A (2020) COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res Clin Pract 162:108137. doi:10.1016/j.diabres.2020.108137
4. Dombrowski NC, Karounos DG (2013) Pathophysiology and management strategies for hyperglycemia for patients with acute illness during and following a hospital stay. Metabolism 62 (3):326-336. doi:10.1016/j.metabol.2012.07.020
5. Targher G, Mantovani A, Wang XB, Yan HD, Sun QF, Pan KH, Byrne CD, Zheng KI, Chen YP, Eslam M, George J, Zheng MH (2020) Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. doi:10.1016/j.diabet.2020.05.001
6. Huang I, Lim MA, Pranata R (2020) Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 14 (4):395-403. doi:10.1016/j.dsx.2020.04.018
7. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev n/a (n/a):e3319. doi:10.1002/dmrr.3319
8. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, Feng J, Yan S, Guan Y, Xu D, He G, Chen C, Xiong X, Liu L, Li H, Tao J, Peng Z, Wang W (2020) Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care:dc200598. doi:10.2337/dc20-0598
9. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, Southern WN, Mantzoros CS (2020) Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism - Clinical and Experimental 108. doi:10.1016/j.metabol.2020.154262
10. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. doi:10.1016/S0140-6736(20)31189-2
11. Sardu C, D’Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R (2020) Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control? Diabetes Care:dc200723. doi:10.2337/dc20-0723
12. D'Agostino RB (1971) An Omnibus Test of Normality for Moderate and Large Size Samples. Biometrika 58 (2):341-348. doi:10.2307/2334522
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395 (10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
14. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal statistical society: series B (Methodological) 57 (1):289-300
15. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, Chen L, Han D, Fan Y, Zeng Y (2020) Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study. Diabetes Res Clin Pract
16. Fadini GP, Morieri ML, Longato E, Avogaro A (2020) Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 43 (6):867-869. doi:10.1007/s40618-020-01236-2
17. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K (2020) Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care:dc200660. doi:10.2337/dc20-0660
18. Angelidi AM, Belanger MJ, Mantzoros CS COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism - Clinical and Experimental. doi:10.1016/j.metabol.2020.154245
19. Joshi N, Caputo GM, Weitekamp MR, Karchmer A (1999) Infections in patients with diabetes mellitus. N Engl J Med 341 (25):1906-1912
20. Geerlings SE, Hoepelman AI (1999) Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26 (3-4):259-265
21. Berbudi A, Rahmadika N, Cahyadi A, Ruslami R (2019) Type 2 Diabetes and its Impact on the Immune System. Current Diabetes Reviews
22. Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, Ma Z, Cao Q, Deng L, Song S (2020) Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv
23. Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ (2020) Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. medRxiv:2020.2005.2020.20108555. doi:10.1101/2020.05.20.20108555
24. Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E, Voltan G, Falaguasta D, Tresso S, Costantini G, Sparacino G, Di Camillo B, Tramontan L, Cattelan AM, Vianello A, Fioretto P, Vettor R, Avogaro A (2020) Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case–control study. Diabetes, Obesity and Metabolism. doi:10.1111/dom.14097
25. Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44 (6):457-464. doi:10.1016/j.diabet.2018.09.005
26. Bossi AC, Forloni F, Colombelli PL (2020) Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends. Diabetes Ther:1-2. doi:10.1007/s13300-020-00844-8
27. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G (2020) Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. doi:10.1056/NEJMoa2006923